Vascularity of primary and metastatic renal cell carcinoma specimens

Journal of Translational Medicine

Research

Robert L Camp¹  Adebowale Adeniran¹  John W Colberg²  Saadia A Aziz³  Joshua Sznol³  Harriet M Kluger⁴ 

[1] Department of Pathology, Yale University School of Medicine, New Haven, CT, USA;Department of Urology, Yale University School of Medicine, New Haven, CT, USA;Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA;Department of the School of Medicine, Yale University School of Medicine, New Haven, CT, USA;Section of Medical Oncology, Yale Cancer Center, 333 Cedar St. WWW213, 06520, New Haven, CT, USA;

关键词: Renal cell carcinoma;    Microvessel area;    Angiogenesis;   

DOI  :  10.1186/1479-5876-11-15

 received in 2012-08-15, accepted in 2013-01-09,  发布年份 2013

来源: Springer

【 摘 要 】

PurposeAnti-angiogenic therapies are among the most commonly used drugs in renal cell carcinoma. Tumor vascularity, defined by microvessel area, may be associated with response to these drugs. Clinical studies suggest that metastatic sites are more responsive than primary tumors. Our purpose was to characterize microvessel area (MVA) in matched primary and metastatic samples and in samples of different histologies.MethodsWe employed a method of automated, quantitative analysis of in situ tumor components to identify the area of CD-34 staining endothelial cells within renal cell carcinoma tumors. MVA was assessed in corresponding primary and metastatic samples from 34 patients, as well as in 334 primary nephrectomy specimens with variable histologies.ResultsMVA measurements from different parts of the same tumor correlated well (R = 0.75), indicating that MVA was fairly uniform within a tumor. While MVA was slightly higher in primary tumors than corresponding metastatic sites, the difference was not statistically significant (P = 0.1). MVA in paired primary and metastatic samples correlated moderately well (R = 0.36). MVA was higher in clear cell than papillary histology and oncocytomas (P < 0.0001 and P = 0.018, respectively).ConclusionsLack of significant differences MVA in matched primary and metastatic samples suggests that both types of tumors should respond to anti-angiogenic drugs. This should be confirmed on additional cohorts. Given the small cohort, future predictive biomarker studies entailing MVA measurements should include specimens from both sites. Clear cell carcinomas are more vascular than other histologic subtypes, which may explain the higher response rates to anti-angiogenic therapies in clear cell tumors.

【 授权许可】

Unknown   
© Aziz et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.